ClinicalTrials.gg
Not yet recruitingNCT07693517SPINE-RISK VEUpdated Jul 10, 2026

SPINE-RISK VE: Multimodal Predictive Model for Failed Back Surgery Syndrome in Venezuelan Surgical Patients

An observational study in Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine, Chronic Low Back Pain and Postoperative Pain, sponsored by juan jose valero quintero,MD. Not yet recruiting at 1 site in Venezuela. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by juan jose valero quintero,MD · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 100 Years
Sex
All
01

Study summary

SPINE-RISK VE is a prospective multicenter cohort study designed to develop and internally validate a multimodal preoperative predictive model for Failed Back Surgery Syndrome (FBSS), now classified as Persistent Spinal Pain Syndrome Type 2 (PSPS-T2) per ICD-11 (code MG30.51), in Venezuelan adults patients undergoing elective lumbar spine surgery.

The model integrates three variable domains obtainable from routine preoperative evaluation at zero additional cost to the patient: (1) inflammatory laboratory biomarkers (C-reactive protein [CRP], neutrophil-to-lymphocyte ratio [NLR], albumin, glycated hemoglobin [HbA1c], erythrocyte sedimentation rate [ESR]); (2) preoperative lumbar magnetic resonance imaging (MRI) findings (Modic changes, Pfirrmann disc degeneration grade, foraminal stenosis, number of surgical levels, spondylolisthesis); and (3) validated psychosocial instruments (Patient Health Questionnaire-9 [PHQ-9], Pain Catastrophizing Scale [PCS], smoking status, benzodiazepine use, prior lumbar surgery).

Analysis proceeds in two phases: Phase 1 applies multivariable logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) variable selection to generate a printable clinical nomogram; Phase 2 applies a random forest machine learning algorithm with 10-fold cross-validation. Model reporting follows Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis plus Artificial Intelligence (TRIPOD+AI) guidelines.

SPINE-RISK VE aims to produce the first validated multimodal predictive model for PSPS-T2/FBSS was developed in a Latin American surgical cohort, providing neurosurgeons with an evidence-based preoperative risk stratification tool applicable without Additional technological infrastructure.

Read the detailed description

Failed Back Surgery Syndrome (FBSS), formally reclassified as Persistent Spinal Pain Syndrome Type 2 (PSPS-T2) in ICD-11 (code MG30.51), affects 10-40% of patients undergoing lumbar spine surgery and constitutes one of the most complex therapeutic challenges in contemporary neurosurgery. Despite the identification of individual risk factors in the literature, no validated multimodal predictive model integrating laboratory biomarkers, lumbar magnetic resonance imaging (MRI) morphology, and psychosocial variables exist for Latin American surgical populations.

The best available predictive model to date achieved Area Under the Receiver Operating Characteristic Curve (AUC) of 0.715 for decompression and 0.701 for fusion using only electronic health record variables, without laboratory biomarkers or MRI-derived predictors, and without validation in any Latin American cohort. SPINE-RISK VE addresses this gap through a prospective multicenter cohort design enrolling 100-150 adults with Elective lumbar surgery indication at three Venezuelan referral centers.

PREDICTOR DOMAINS:

Domain 1 - Inflammatory biomarkers:

C-reactive protein (CRP greater than 3 mg/L), neutrophil-to-lymphocyte ratio (NLR greater than 3.0), serum albumin (less than 3.5 g/dL), glycated hemoglobin (HbA1c greater than 7%), and erythrocyte sedimentation rate (ESR). All obtainable from standard preoperative Laboratory panels.

Domain 2 - Lumbar MRI findings: Modic changes (Types I-III), disc degeneration grade (Pfirrmann scale I-V), foraminal stenosis, number of surgical levels, and Spondylolisthesis grade (Meyerding I-IV). All from already-requested preoperative imaging.

Domain 3 - Psychosocial factors: depression (Patient Health Questionnaire-9 [PHQ-9] cutoff of 10 or greater), pain catastrophizing (Pain Catastrophizing Scale [PCS] cutoff of 30 or greater, active smoking, preoperative benzodiazepine use, and prior lumbar surgery history.

PRIMARY OUTCOME: PSPS-T2/FBSS incidence at 12 months, defined as the Numeric Rating Scale (NRS) of 4 or greater AND Oswestry Disability Index (ODI) of 40% or greater at postoperative follow-up, consistent with International Association for the Study of Pain (IASP) criteria.

ANALYTICAL PLAN:

Phase 1: Multivariable logistic regression with Least Absolute Shrinkage and Selection Operator (LASSO) regularization to identify independent predictors and generate a Printable clinical nomogram. Software: R Version 4.x (glmnet, rms packages).

Phase 2: Random forest (500 trees, 10-fold cross-validation) compared against Extreme Gradient Boosting (XGBoost) and logistic regression. Performance metrics: AUC-ROC (target 0.80 or greater), sensitivity, specificity, calibration (Hosmer-Lemeshow test, Brier score). Model interpretability via SHapley Additive exPlanations (SHAP) values.

REPORTING: Transparent Reporting of a multivariable prediction model for an individual Prognosis Or Diagnosis plus Artificial Intelligence (TRIPOD+AI) 2024 and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

EXPECTED OUTPUTS: (1) Printable preoperative nomogram applicable without additional technological infrastructure; (2) exportable machine learning (ML) model with AUC target of 0.80 or greater; (3) first structured lumbar surgery database with 12-month Follow-up generated in Venezuela.

02

Conditions studied

  • Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine
  • Chronic Low Back Pain
  • Postoperative Pain
  • Lumbar Spine Surgery

Browse trials for

Keywords

  • predictive model
  • machine learning
  • random forest
  • LASSO regression
  • Modic changes
  • inflammatory biomarkers
  • pain catastrophizing
  • TRIPOD+AI
  • Venezuela
  • Latin America
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 150 is above the median of 102 across 683 observational studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with juan jose valero quintero,MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with degenerative lumbar spine disease undergoing elective lumbar surgery (discectomy, spinal fusion, or decompression) at three Venezuelan referral centers: Hospital Universitario de Caracas and two regional Neurosurgical referral centers in Venezuela. Consecutive recruitment during the study period. This population represents a low-middle income country (LMIC) Latin American surgical cohort not previously represented in published predictive models for PSPS-T2/FBSS

Eligibility criteria

Inclusion Criteria:- Age 18 years or older

  • Confirmed indication for elective lumbar spine surgery (discectomy, spinal fusion, or decompression) for degenerative lumbar disease
  • Availability of preoperative lumbar MRI (with and without gadolinium contrast) within 6 months before surgery
  • Availability of standard preoperative laboratory panel (CRP, CBC with differential, albumin, , ESR) within 30 days before surgery
  • Ability to complete validated psychosocial instruments (PHQ-9, PCS) in Spanish
  • Provision of written prior to any study procedure
  • Attending one of the three participating Venezuelan referral centers during the recruitment period

Exclusion Criteria:- Emergency lumbar spine surgery

  • Active spinal infection or spinal tumor requiring oncological surgery
  • Traumatic spinal fracture as primary indication
  • Cognitive impairment preventing completion of self-report psychosocial instruments
  • Active psychiatric emergency at time of preoperative assessment
  • Prior participation in another clinical trial that could influence surgical or pain outcomes
  • Inability to complete 12-month postoperative follow-up (geographic inaccessibility, planned relocation, or terminal illness)
  • Age under 18 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lumbar surgery candidates

    Adult patients (18 years or older) with an indication for elective lumbar spine surgery (discectomy, spinal fusion, or decompression) for degenerative lumbar disease at three Venezuelan referrals centers. All participants undergo standardized preoperative assessment, including inflammatory laboratory biomarkers, lumbar MRI morphological evaluation, and validated psychosocial instruments (PHQ-9, PCS). The primary outcome assessed at 12-month postoperative follow-up.

    Other: SPINE-RISK VE multimodal preoperative assessment

Interventions

  • OtherSPINE-RISK VE multimodal preoperative assessment

    Adult patients (18 years or older) with an indication for elective lumbar spine surgery (discectomy, spinal fusion, or decompression) for degenerative lumbar disease at three Venezuelan referral centers. All participants undergo standardized preoperative assessment, including inflammatory laboratory biomarkers, lumbar MRI morphological evaluation, and validated psychosocial instruments (PHQ-9, PCS). Primary outcome assessed at 12-month postoperative follow-up

06

What researchers measure

Primary outcomes

  1. Predictive accuracy of SPINE-RISK VE model for PSPS-T2/FBSS at 12 months

    Area Under the Receiver Operating Characteristic Curve (AUC-ROC) of the multimodal predictive model (Phase 1: LASSO logistic regression nomogram; Phase 2: random forest algorithm) for identifying patients who develop Persistent Spinal Pain Syndrome Type 2 (PSPS-T2/FBSS) at 12 months post-lumbar surgery, defined as NRS \>=4 AND ODI \>=40% at postoperative follow-up assessment. Target AUC \>=0.80 per Riley et al. (Stat Med 2020) Minimum criteria for clinical prediction models.

    Time frame: 12 months post-lumbar surgery

07

Study locations

1 site
  • Hopsital Universitario de Caracas
    Caracas, Distrito Capitañ 1050, Venezuela
    • juan j valero, Medical Doctor · Contactjuanjoseneuro@gmail.com · 7868055589
    • Edicson j Cardenas, Nursing · Contactedicsonjcardenas@gmail.com · 00584241540328
    • juan j valero, Medical Doctor · Principal investigator
    • Fredy Contreras, PHD · Sub investigator
    • Hector r Aceituno, Medical doctor · Sub investigator
    • Edicson j cardenas, Nursing · Sub investigator
08

References and documents

Publications

  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med. 2007 Oct;45(4):247-51. doi: 10.1016/j.ypmed.2007.08.012. Epub 2007 Sep 4. PubMed 17950122 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗
  • Riley RD, Snell KI, Ensor J, Burke DL, Harrell FE Jr, Moons KG, Collins GS. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019 Mar 30;38(7):1276-1296. doi: 10.1002/sim.7992. Epub 2018 Oct 24. PubMed 30357870 ↗
  • Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378. PubMed 38626948 ↗
  • Xu W, Ran B, Zhao J, Luo W, Gu R. Risk factors for failed back surgery syndrome following open posterior lumbar surgery for degenerative lumbar disease. BMC Musculoskelet Disord. 2022 Dec 31;23(1):1141. doi: 10.1186/s12891-022-06066-2. PubMed 36585650 ↗
  • Hajilo P, Imani B, Zandi S, Mehrafshan A, Khazaei S. Risk factors analysis and risk prediction model for failed back surgery syndrome: A prospective cohort study. Heliyon. 2024 Nov 22;11(1):e40607. doi: 10.1016/j.heliyon.2024.e40607. eCollection 2025 Jan 15. PubMed 39866404 ↗
  • Khazanchi R, Kumar D, Oris RJ, Bajaj A, Herrera DE, Chen AR, Shah RM, Asthana S, Reyes SG, Bajaj P, Hsu WK, Patel AA, Divi SN. Identifying Predictors of Failed Back Surgery Syndrome Following Lumbar Spine Surgery: A Machine Learning Approach. Spine (Phila Pa 1976). 2026 May 15;51(10):736-742. doi: 10.1097/BRS.0000000000005411. Epub 2025 May 29. PubMed 40443211 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. This study collects sensitive clinical and psychosocial data from Venezuelan patients In a low-resource setting. The research team does not have access to formal data repository infrastructure for anonymized IPD sharing that meets international data protection standards. Aggregate study results and the derived predictive model (nomogram and machine learning algorithm) will be made publicly available through peer-reviewed publication In an indexed journal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2027, 14 months later.

Of 391 non-industry observational studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 14 months is close to that.

Counting every sponsor, half of 395 studies reached it within 13 months; a quarter within 5 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2026
First posted
Jul 9, 2026
StartEst.
Sep 4, 2026
Primary completionEst.
Nov 4, 2027
CompletionEst.
Feb 10, 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07693517
Lead sponsor
juan jose valero quintero,MD
Responsible party
juan jose valero quintero,MD (Principal Investigator, Neurosurgeon and Pain Medicine Specialist, Universidad Central de Venezuela) — Sponsor-investigator
First posted
Jul 9, 2026
Start date
Sep 4, 2026 (estimated)
Primary completion
Nov 4, 2027 (estimated)
Completion
Feb 10, 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

juan j Valero, Medical Doctor
Contact
juanjoseneuro@gmail.com
7868055589 ext. 00584224263876
Fredy Contreras, PHD
Contact
sicontreras2009@gmail.com
00584149109021
juan j valero, Medical Doctor
principal investigator · Universidad Central de Venezuela

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion